Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma

详细信息    查看全文

• 作者：Ji Young Lee ; Cheryn Song ; Bum Sik Hong…
• 关键词：Renal cell carcinoma ; Immunotherapy ; Interleukin ; 2 ; Modified regimen
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：79
• 期：1
• 页码：173-180
• 全文大小：
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Oncology; Pharmacology/Toxicology; Cancer Research;
• 出版者：Springer Berlin Heidelberg
• ISSN：1432-0843
• 卷排序：79

文摘

PurposeThe standard regimen of high-dose interleukin-2 (HDIL-2) for metastatic renal cell carcinoma (RCC) is two cycles separated by 9 days, which constitutes one course. Each course is separated by an 8–12 weeks. However, the 9-day interval between each HDIL-2 cycle is often not long enough to allow recovery from adverse effects. Therefore, we modified HDIL-2 schedules by increasing the interval between each cycle without changing the total cumulative doses of IL-2.